Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults

被引:346
作者
Kim, HJ
Kim, HJ
Lee, KE
Kim, DJ
Kim, SK
Ahn, CW
Lim, SK
Kim, KR
Lee, HC
Huh, KB
Cha, BS
机构
[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul, South Korea
[3] Kwa Dong Univ, Coll Med, Dept Internal Med, Goyang, Peoples R China
[4] Ajou Univ, Sch Med, Dept Endocrinol & Metab, Suwon 441749, South Korea
关键词
D O I
10.1001/archinte.164.19.2169
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Obesity and type 2 diabetes are well-known risk factors for the development of nonalcoholic fatty liver disease (NAFLD). However, NAFLD is not rare in nonobese, nondiabetic adults. The aim of this study was to evaluate the metabolic significance of NAFLD in nonobese, nondiabetic adults. Methods: This study examined 768 nonobese (body mass index [BMI] [calculated as weight in kilograms divided by the square of height in meters], greater than or equal to18.5 and <30) (460 normal-weight and 308 overweight subjects), nondiabetic individuals older than 30 years who participated in a medical checkup. All the subjects had negative serologic findings for hepatitis B and C viruses and had an alcohol intake less than 140 g/wk. A standard interview, anthropometrics, a biochemical study, and abdominal ultrasonography were conducted. Results: The prevalence of NAFLD in the enrolled subjects was 23.4%. In the normal-weight (BMI, greater than or equal to18.5 and<25) and overweight (BMI, greater than or equal to25 and <30) groups, NAFLD was a significant predictor of insulin resistance and other metabolic disorders, including hypertriglyceridemia and hyperuricemia. The odds ratio of the metabolic disorders in subjects with NAFLD compared with those without NAFLD in the normal-weight group was higher than that in the overweight group. Multiple logistic regression analysis showed that sex, waist circumference, triglyceride level, and insulin resistance were independently associated with NAFLD in the normal-weight group. Conclusions: Nonalcoholic fatty liver disease is closely associated with metabolic disorders, even in nonobese, nondiabetic subjects. Nonalcoholic fatty liver disease can be considered an early predictor of metabolic disorders, particularly in the normal-weight population.
引用
收藏
页码:2169 / 2175
页数:7
相关论文
共 43 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]  
[Anonymous], 1998, Obes Res, V6, p51S
[4]   A clinical trial of the effects of dietary patterns on blood pressure [J].
Appel, LJ ;
Moore, TJ ;
Obarzanek, E ;
Vollmer, WM ;
Svetkey, LP ;
Sacks, FM ;
Bray, GA ;
Vogt, TM ;
Cutler, JA ;
Windhauser, MM ;
Lin, PH ;
Karanja, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (16) :1117-1124
[5]  
Araújo LMB, 1998, DIABETES METAB, V24, P458
[6]   NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109
[7]   Prevalence of and risk factors for hepatic steatosis in northern Italy [J].
Bellentani, S ;
Saccoccio, G ;
Masutti, F ;
Crocè, LS ;
Brandi, G ;
Sasso, F ;
Cristanini, G ;
Tiribelli, C .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) :112-117
[8]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]  
COATES RA, 1986, CLIN INVEST MED, V9, P26